News + Filings Key Docs Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
MAINZ BIOMED N.V.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/26/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/15/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"REPORT OF FOREIGN PRIVATE ISSUER",
"MANAGEMENT’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION",
"Mainz Biomed N.V. Condensed Interim Consolidated Statements of Financial Position . June 30, December 31, Note 2023 2022 ASSETS Current Assets Cash $ 10,911,087 $ 17,141,775 Trade and other receivables, net 4 370,931 259,138 Inventories 387,178 175,469 Prepaid expenses 5 455,934 801,959 Total current assets 12,125,130 18,378,341 Property and equipment, net 6 1,617,228 661,692 Intangible assets 7 3,630,384 - Right-of-use assets 8 1,932,258 1,177,695 Other assets 106 23,275 Total assets $ 19,305,106 $ 20,241,003 LIABILITIES AND SHAREHOLDERS’ EQUITY Current Liabilities Accounts payable and accrued liabilities 9 $ 4,326,662 $ 2,916,679 Convertible loan 11 43,637 43,057 Convertible promissory note at fair value 11 5,015,000 - Convertible debt - related party 10 32,615 32,181 Silent partnership ...",
"Forward-Looking Statements" |
|
| 07/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 07/11/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 06/28/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 06/28/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/19/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/16/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/01/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/20/2023 |
6-K
| Quarterly results |
| 01/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 01/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/30/2022 |
F-3
| Form F-3 - Registration statement by foreign private issuers: |
| 12/20/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 11/04/2022 |
6-K
| Quarterly results |
| 09/06/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"REPORT OF FOREIGN PRIVATE ISSUER",
"MANAGEMENT’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION",
"December 31, 2021 Current portion $ 114,669 $ 55,076 Long-term portion 475,148 387,766 Total lease liabilities $ 589,817 $ 442,842 At June 30, 2022, the Company is committed to minimum lease payments as follows: Maturity analysis June 30, 2022 Less than one year $ 77,108 One to two years 154,216 Two to three years 151,782 Three to four years 95,580 Four to five years 82,443 More than five years 133,238 Total undiscounted lease liabilities $ 694,367 Amount representing implicit interest Lease obligations $ 589,817 7. ACCOUNTS PAYABLE AND ACCRUED EXPENSES June 30, December 31, 2022 2021 Accounts payable $ 503,181 $ 747,768 Accrued liabilities 51,633 26,989 Payroll liabilities 50,974 6,812 Bonus accrual 600,000 - VAT payable - 3,217 $ 1,205,788 $ 784,786 8. CONVERTIBLE DEBT – RELATED PARTY Du...",
"Mainz Biomed Reports First Half 2022 Financial Results ● 127% year-over-year increase in ColoAlert revenue ● Mid-year cash balance of $26 Million BERKELEY, US – MAINZ, Germany – September 7, 2022 — Mainz Biomed N.V. , a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the first half of the fiscal year ended June 30, 2022. Key Corporate & Product Development Highlights ● Accelerated international commercial activities for ColoAlert, the Company’ s highly efficacious and easy-to-use detection test for colorectal cancer ● Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer ● Established partnership with Dante Labs to market ColoAlert in Italy and the Unit..." |
|
| 07/01/2022 |
6-K
| Quarterly results |
| 06/03/2022 |
6-K
| Quarterly results |
| 05/16/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/16/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/02/2022 |
NT 20-F
| Form NT 20-F - Notification of inability to timely file Form 20-F: |
| 01/28/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 01/28/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"REPORT OF FOREIGN PRIVATE ISSUER",
"Underwriting Agreement, between Mainz Biomed N.V. and Boustead Securities, LLC",
"Mainz Biomed Announces Pricing of Follow-on Offering BERKELEY, Calif. and MAINZ, Germany, Jan. 25, 2022 -- Mainz Biomed N.V. , a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the pricing of its underwritten public follow-on offering of 1,500,000 ordinary shares at a public offering price of US$15.00 per ordinary share , for gross proceeds of $22,500,000. The Follow-on Offering is being made pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission . The Follow-on Offering is expected to close on January 28, 2022, subject to the satisfaction of customary closing conditions. In connection with the Follow-on Offering, Mainz Biomed has granted the underwriter the option to purchase up to 225,00...",
"Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Proceeds Allocated to Development of Recently Acquired mRNA Biomarkers and Launch of Clinical Studies to Support ColoAlert’ s FDA Submission BERKELEY, US – MAINZ, Germany – JANUARY 28, 2022 — Mainz Biomed N.V. , a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the closing of its underwritten public follow-on offering of 1,725,000 ordinary shares at a public offering price of US$15.00 per ordinary share . The aggregate gross proceeds to Mainz Biomed were $25,875,000 before deducting underwriting discounts and commissions and other offering expenses payable. This incl..." |
|
| 01/26/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/21/2022 |
F-1
| Form F-1 - Registration statement for certain foreign private issuers: |
| 01/06/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 11/12/2021 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"REPORT OF FOREIGN PRIVATE ISSUER",
"Underwriting Agreement, between Mainz Biomed N.V. and Boustead Securities, LLC",
"Deed of Conversion",
"MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market BERKELEY, US – MAINZ, Germany – NOVEMBER 5, 2021 — Mainz Biomed N.V. , a molecular genetics diagnostics company specializing in the early detection of cancer, announces that its shares have commenced trading today on the Nasdaq Capital Market under the ticker symbol “MYNZ”. On November 4, 2021, the Company priced its firm commitment underwritten public offering of 2,000,000 common shares at a public offering price of $5.00 per share. The gross proceeds to the Company from the Offering will be $10,000,000, before deducting underwriting discounts, commissions and other expenses. The Offering is expected to close on or about November 9, 2021, subject to customary closing conditions. The securities described above are being sold b...",
"Mainz Biomed Announces Exercise of Over-Allotment Option BERKELEY, Calif. and MAINZ, Germany, Nov. 08, 2021 -- Mainz Biomed N.V. , a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the underwriters have exercised their over-allotment option resulting in the issuance of an additional 300,000 shares. Mainz Biomed had previously announced the pricing of its $10 Million public offering of 2,000,000 shares on November 4th, 2021 at $5.00 per share. With the exercise and closing of the underwriters' over-allotment option, the total gross proceeds to the Company are $11.5 Million. The Company commenced trading on the Nasdaq Capital Market on November 5th, 2021. Boustead Securities, LLC acted as sole underwriter for the Offering. The securities d..." |
|
| 11/12/2021 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/12/2021 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/03/2021 |
CERT
| Form CERT - Certification by an exchange approving securities for listing: |
| 11/03/2021 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 10/26/2021 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 10/26/2021 |
F-1/A
| Form F-1/A - Registration statement for certain foreign private issuers: [Amend] |
| 10/08/2021 |
F-1
| Form F-1 - Registration statement for certain foreign private issuers: |
|
|